FDA Approves Alcon's Patanase Nasal Spray
Posted on: Wednesday, 16 April 2008, 12:01 CDT
Alcon has announced that the FDA has approved Patanase nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older.
The FDA approval of Patanase nasal spray was based primarily on multiple clinical studies for the evaluation of safety, efficacy and onset of action. The results of these clinical studies were that patients treated with Patanase, two sprays per nostril, twice daily, demonstrated significantly greater decreases in total nasal symptom scores (TNSS) compared to the placebo nasal spray.
Patanase nasal spray, an extension to the company's market-leading ocular allergy product line, will be available in May, 2008.
Kevin Buehler, Alcon's senior vice president, global markets and chief marketing officer, said: "We look forward to providing doctors the opportunity to prescribe Patanase to their patients who need and want a fast-acting nasal spray that quickly relieves symptoms."
Source: Datamonitor
Related Articles
- OMNARIS(TM) Nasal Spray Now Available By Prescription for Patients With Seasonal and Perennial Allergies
- Alcon's PATANASE(R) Nasal Spray Approved By FDA for Treatment of Nasal Allergy Symptoms
- Alcon Amends NDA for Patanase(R) Nasal Spray
- Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
- Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
- Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis
- Survey Shows Discomfort With Existing Nasal Sprays Causes Allergic Rhinitis Patients to Discontinue Treatment
- Alcon Presents New Clinical Data and Provides Regulatory Update on PATANASE(R) Nasal Spray
- Beat the Flu This Year With Nasal Spray
 |
 |
User Comments (0)
RSS Feeds